Literature DB >> 12818625

Medical management of biological warfare and bioterrorism: place of the immunoprevention and the immunotherapy.

Patrice Binder1, Olivier Attre, Jean Paul Boutin, Jean Didier Cavallo, Thierry Debord, Alain Jouan, Dominique Vidal.   

Abstract

Biological weapons are considered as mass destruction and terror weapons. Terrorism including bioterrorism is the major threat in the future conflicts for our nations. The aim of bioterrorism is more related to the potential disorganisation of the society than to the lethal effects of the agents used. The dramatic consequences cannot be discarded, especially if contagious agents such viral are used. The preparation of specific defence measures is a major challenge for our countries. The knowledge acquired from the struggle against natural infectious diseases and recent events are essential to improve behaviours to face the biological weapon threats. The defence attitude is based on the anticipation of the threat, the management of the victims, and the restoration of the operational capabilities. This global defence attitude implies six important functions: (i) alert, (ii) detection and diagnosis, (iii) availability of pharmaceutical countermeasures such as vaccine, sera and anti-infectious medicine and products, (iv) medical management of victims, (v) training and information, (vi) research and development. Passive and active immunoprevention and immuntherapy belong to the approaches discussed in the context of bioterrorism countermeasures. Further researches might be focused on these topics.

Entities:  

Mesh:

Year:  2003        PMID: 12818625     DOI: 10.1016/S0147-9571(03)00023-7

Source DB:  PubMed          Journal:  Comp Immunol Microbiol Infect Dis        ISSN: 0147-9571            Impact factor:   2.268


  4 in total

1.  Neutralising antibodies against ricin toxin.

Authors:  Julie Prigent; Laetitia Panigai; Patricia Lamourette; Didier Sauvaire; Karine Devilliers; Marc Plaisance; Hervé Volland; Christophe Créminon; Stéphanie Simon
Journal:  PLoS One       Date:  2011-05-25       Impact factor: 3.240

2.  Ricin Antibodies' Neutralizing Capacity against Different Ricin Isoforms and Cultivars.

Authors:  Maria Lucia Orsini Delgado; Arnaud Avril; Julie Prigent; Julie Dano; Audrey Rouaix; Sylvia Worbs; Brigitte G Dorner; Clémence Rougeaux; François Becher; François Fenaille; Sandrine Livet; Hervé Volland; Jean-Nicolas Tournier; Stéphanie Simon
Journal:  Toxins (Basel)       Date:  2021-01-29       Impact factor: 4.546

3.  Humanization and characterization of an anti-ricin neutralization monoclonal antibody.

Authors:  Wei-Gang Hu; Junfei Yin; Damon Chau; Laurel M Negrych; John W Cherwonogrodzky
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

4.  Conformation-dependent high-affinity potent ricin-neutralizing monoclonal antibodies.

Authors:  Wei-Gang Hu; Junfei Yin; Damon Chau; Charles Chen Hu; Dustin Lillico; Justin Yu; Laurel M Negrych; John W Cherwonogrodzky
Journal:  Biomed Res Int       Date:  2012-12-26       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.